Tuberculosis and HIV

Tuberculosis and HIV features

• 

  HIV and TB in Practice for nurses: Pregnancy and TB/HIV

  This article explains how to prevent and treat TB in pregnant women to protect both mother and child....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: Drug-resistant TB

  This article summarises the key recommendations on the diagnosis and treatment of drug-resistant TB for nurses, and highlights examples of best practice in their care....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: TB infection control

  This article provides practical information for nurses on TB infection control....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: Starting ART for treatment and prevention in people with active TB and HIV

  This article provides information for nurses on starting HIV treatment for people with HIV and active TB....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice: Moving towards combination TB prevention

  This article looks at research on TB prevention, in particular the move towards combination TB prevention....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: TB symptom screening and linking to diagnosis and care

  This edition looks at the practicalities of symptom screening and keeping track of patients during the diagnostic process....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: active TB case finding

  The role of nurses and community health workers in the identification of TB in people living with HIV and in the wider community. ...

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: ART and TB prevention

  This edition is particularly intended for nurses and community health workers interested in TB and HIV....

  From:  HIV & AIDS treatment in practice

• 

  New laboratory tests to enhance TB diagnosis: Microscopy, LAM and Xpert MTB/RIF used as a drug resistance test

  The third in a series looking at the implications of new laboratory tests for TB diagnosis, particularly in people living with HIV. ...

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: non-communicable diseases, HIV and TB

  Conditions such as cancer, heart disease and diabetes in low- and middle-income countries, and awareness of these conditions in people living with HIV and/or TB. ...

  From:  HIV & AIDS treatment in practice

Tuberculosis and HIV in your own words

• 

  TB - my experiences

  This might sound odd, but I was really shocked when I became seriously ill because of HIV. I was even more shocked when it turned...

  From: In your own words

Tuberculosis and HIV news from aidsmap

• Steroids reduce mortality risk for people taking TB treatment

  Corticosteroid treatment is associated with a reduced risk of mortality for people taking tuberculosis (TB) therapy, results of a meta-analysis published in The Lancet Infectious Diseases show. Treatment with steroids was associated with a significant 17% reduction in mortality risk, ...

  24 March 2013 | Michael Carter

• Dosing of key TB drug rifampicin could go higher

  Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at much higher doses than used in current clinical practice – suggesting that much higher drug levels may lead to a more rapid treatment response, allowing the treatment ...

  07 March 2013 | Keith Alcorn

• Once-weekly continuation phase TB treatment equals standard of care

  A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis (TB) treatment to be taken once-weekly during the four-month continuation phase, Dr Amina Jindani of St George’s University Medical School, London, told the 20th Conference on Retroviruses and ...

  07 March 2013 | Keith Alcorn

• In resource-rich countries, migrants have a higher risk of progressing to AIDS in the first year of HIV therapy

  Rates of AIDS-defining illnesses in the first year of antiretroviral therapy are significantly higher among migrant than non-migrant populations in resource-rich countries, investigators report in the online edition of AIDS. The difference was mainly driven by higher rates of tuberculosis ...

  01 March 2013 | Michael Carter

• Results of TB vaccine trial give cause for optimism, say researchers

  Results of a trial have been praised for “providing hard evidence about protection against tuberculosis in human beings”. The MVA85A vaccine did not confer any additional protection against tuberculosis (TB) or infection with Mycobacterium tuberculosis to infants who had ...

  04 February 2013 | Michael Carter

• Hospital exposure the source of XDR-TB infections, underlining the need for adequate infection control

  Numerous hospital transmissions – rather than a single source – fuelled the outbreak of extensively drug-resistant tuberculosis (XDR-TB) at Tugela Ferry, South Africa, in 2005-06, research published in the online edition of the Journal of Infectious Diseases shows. Epidemiological ...

  30 January 2013 | Michael Carter

• Steep fall in incidence of TB among HIV-positive heterosexuals in the UK

  Incidence of tuberculosis (TB) among HIV-positive heterosexual people in England and Wales declined significantly between 2002 and 2010, investigators report in the online edition of AIDS. The fall is attributed to changes in the epidemiology of HIV in the ...

  15 January 2013 | Michael Carter

• Aggressive therapy for MDR-TB reduces risk of disease recurrence

  Aggressive treatment of multidrug-resistant tuberculosis (MDR-TB) significantly reduces the risk of disease recurrence, investigators report in the online edition of Clinical Infectious Diseases. Patients who received intensive therapy for at least 18 months after cure were 60% less ...

  31 December 2012 | Michael Carter

• Vitamin D deficiency increases risk of TB among people starting HIV therapy

  Vitamin D deficiency is associated with an increased risk of pulmonary tuberculosis (TB), oral thrush and wasting among people starting HIV therapy in Tanzania, investigators report in the online edition of the Journal of Infectious Diseases. People with vitamin D ...

  19 December 2012 | Michael Carter

• FDA Advisory Committee recommends accelerated approval of bedaquiline for drug-resistant TB

  Bedaquiline, the first agent in a new class of TB drug, has been recommended for accelerated approval by the Anti-Infective Drugs Advisory Committee of the United States Food and Drug Administration (FDA). The committee voted unanimously (18 to 0) ...

  03 December 2012 | Lesley Odendal

More news

Tuberculosis and HIV news selected from other sources

• Book Review: The Plague That Refuses to Go Away

  Jasmine Grenier and Madhukar Pai from McGill University review “Spitting Blood: The History of Tuberculosis” by Helen Bynum.

  16 May 2013 | PLoS Blogs (blog)

• Lesotho to Expand HIV and Tuberculosis Programs

  [Global Fund]Maseru, Lesotho -The Global Fund to Fight AIDS, Tuberculosis and Malaria announced today that it is signing two grant agreements with the Ministry of Finance of Lesotho totaling US$17 million, to allow Lesotho to expand prevention and treatment of HIV and multidrug resistant tuberculosis (MDR-TB).

  09 May 2013 | AllAfrica

• The ongoing problem of tuberculosis in the UK

  The report of the All-Party Group on Global Tuberculosis gives grounds for optimism; although the task is huge it provides a coherent set of recommendations that can be taken on by a new public health body seeking to demonstrate its leadership and effectiveness. Successfully leading the strategy to eliminate tuberculosis in the UK should be an agreed metric to measure the performance of Public Health England.

  26 April 2013 | The Lancet (editorial)

• Most HIV patients in Papua co-infected with TB

  An official said Wednesday that around 60 percent of HIV-infected people in Papua are known to have also suffered from tuberculosis (TB) and that up to 40 percent of TB patients in the province are also HIV-positive.

  26 April 2013 | Jakarta Post

• Researchers make a significant step forward in combating antibiotic resistance

  Antibiotic resistance is a global problem. The World Health Organisation (WHO) estimates that for tuberculosis alone multi-drug resistance accounts for more than 150,000 deaths each year. Now researchers are one step closer to understanding why antibiotics are ineffective against certain types of bacteria.

  25 April 2013 | Durham University News

• Tuberculosis prevention may speed drug resistance

  According to the new study, led by Harriet Mills at the University of Bristol, in communities that implement isoniazid preventive therapy (IPT), the incidence of new isoniazid-resistant cases per year will double in the next 40 years.

  15 April 2013 | Nature

• Rifapentine’s manufacturer helps to advance TB research while stalling access

  Sanofi-Aventis, manufacturer of the tuberculosis (TB) drug rifapentine (Priftin), can be credited for aiding research efforts to shorten and simplify treatment dosing for TB. However, the company’s pricing of the drug has hampered access to such regimens, even in resource-rich nations like the United States.

  12 April 2013 | Treatment Action Group

• Significant Declines in TB Incidence, Prevalence and Mortality, but MDR-TB Remains a Threat

  TB mortality has decreased significantly since 2000 and treatment success rates have shown steady improvement. More than half of the countries that have received Global Fund support are on track to meet the international targets for case detection, treatment success, and TB disease incidence. However, multi-drug-resistant TB (MDR-TB) remains a critical threat.

  09 April 2013 | Global Fund Observer

• The Search for Swaziland’s TB-Infected Mine Workers

  “Mine workers come from the whole sub-region to our mines to catch TB and HIV and take it back to their families and communities,” South African Minister of Health Dr. Aaron Motsoaledi said.

  09 April 2013 | Inter Press Service

• World TB Day - The Lancet special edition

  To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO.

  26 March 2013 | Lancet Infectious Diseases

More news